Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone/bupropion (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Registrational
  • Acronyms LIGHT; Light Study
  • Sponsors Orexigen Therapeutics [CEASED]; Takeda

Most Recent Events

  • 15 Jun 2021 Results of post-hoc analysis assessing safety and efficacy of NB and placebo among individuals with overweight or obesity who were also taking antidepressant therapy during the LIGHT trial, published in the Journal of Affective Disorders
  • 04 Sep 2020 Results of post hoc analysis of data from the 6 naltrexone ER/bupropion ER trials assessing the percent of subjects achieving a weight loss of 5% to 10%, 10% to 15%, and more than 15% at weeks 16, 52, 104, and 208 presented at the 2020 European and International Congress on Obesity
  • 20 May 2017 Results assessing the effect of Naltrexone/Buproplon on body weight of overweight and obese participants with elevated cardiovascular risk, presented at the 24th European Congress on Obesity.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top